SCHEMBL5136269

SCHEMBL5136269

CCCCN(Cc1ccc(Cl)cc1)Cc1c(-c2ccccc2)nc(-c2ccccc2)n1CCC

nearest known ligand 0.42

Predicted protein targets (top 10)

geneUniProtsupporting neighboursconfidence
CRHR1 P34998 5/20 0.42
C5AR1 P21730 1/20 0.41
ALDH1A1 P00352 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
SLC2A1 P11166 1/20 0.38
ATP4A P20648 1/20 0.37
ATP4B P51164 1/20 0.37
TSHR P16473 1/20 0.37
HSD11B1 P28845 1/20 0.37
KCNH2 Q12809 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5136524 0.96 C5AR1 (0.46) CRHR1C5AR1ALDH1A1SMN1; SMN2SLC2A1
SCHEMBL5134950 0.95 C5AR1 (0.45) CRHR1C5AR1ALDH1A1SLC2A1ATP4A
SCHEMBL5136887 0.95 C5AR1 (0.43) CRHR1C5AR1ALDH1A1TSHRHSD11B1
SCHEMBL5135824 0.94 C5AR1 (0.44) CRHR1C5AR1ALDH1A1SLC2A1ATP4A
SCHEMBL5134816 0.92 CRHR1 (0.44) CRHR1C5AR1ALDH1A1ATP4AATP4B
SCHEMBL5136847 0.92 MAPT (0.44) CRHR1C5AR1ALDH1A1SLC2A1ATP4A
SCHEMBL5134667 0.92 C5AR1 (0.43) CRHR1C5AR1ALDH1A1SLC2A1TSHR
SCHEMBL5136560 0.92 C5AR1 (0.46) CRHR1C5AR1ALDH1A1SMN1; SMN2SLC2A1
SCHEMBL5135599 0.92 C5AR1 (0.43) CRHR1C5AR1ALDH1A1ATP4AATP4B
SCHEMBL5135456 0.92 C5AR1 (0.43) CRHR1C5AR1ALDH1A1ATP4AATP4B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1490044-A4 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORP (US) 2008-04-16 EP disclosed
EP-1490044-A1 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORPORATION (US) 2004-12-29 EP disclosed
WO-2003084524-A1 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORPORATION (US) 2003-10-16 WO disclosed